Campbells Co (CPB) concluded trading on Thursday at a closing price of $34.17, with 4.5 million shares of worth about $153.69 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -24.55% during that period and on May 29, 2025 the price saw a gain of about 1.12%. Currently the company’s common shares owned by public are about 298.00M shares, out of which, 196.45M shares are available for trading.
Stock saw a price change of -0.18% in past 5 days and over the past one month there was a price change of -5.19%. Year-to-date (YTD), CPB shares are showing a performance of -18.41% which decreased to -24.64% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $32.95 but also hit the highest price of $52.81 during that period. The average intraday trading volume for Campbells Co shares is 3.50 million. The stock is currently trading -2.41% below its 20-day simple moving average (SMA20), while that difference is down -7.23% for SMA50 and it goes to -19.56% lower than SMA200.
Campbells Co (NASDAQ: CPB) currently have 298.00M outstanding shares and institutions hold larger chunk of about 58.40% of that.
The stock has a current market capitalization of $10.19B and its 3Y-monthly beta is at 0.11. PE ratio of stock for trailing 12 months is 19.68, while it has posted earnings per share of $1.74 in the same period. Its PEG reads 12.38 and has Quick Ratio of 0.55 while making debt-to-equity ratio of 2.06. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CPB, volatility over the week remained 2.10% while standing at 1.68% over the month.
Stock’s fiscal year EPS is expected to drop by -3.33% while it is estimated to increase by 1.70% in next year. EPS is likely to shrink at an annualized rate of 1.59% for next 5-years, compared to annual growth of 15.98% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by UBS on April 23, 2025 offering a Sell rating for the stock and assigned a target price of $36 to it. On March 06, 2025, JP Morgan Downgrade their recommendations, while on November 14, 2024, Piper Sandler Upgrade their ratings for the stock with a price target of $56. Stock get an Outperform rating from Bernstein on October 07, 2024.
